Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002825 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL4999728 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL4999828 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL4999549 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL4999554 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL4999832 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL5002820 | 1.00 | GAA (0.55) | GAAMAPTPLA2G1BATG4BKDM4E | |
| SCHEMBL5005176 | 0.84 | GAA (0.50) | GAAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4996044 | 0.84 | GAA (0.50) | GAAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL5002696 | 0.84 | GAA (0.50) | GAAMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1840126-A1 | 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | CYP11B2, CYP11B1, GRIN2A | GAA 3365/4885MAPT 549/4885PLA2G1B 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.